Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006290 · ClinicalTrials.gov registry record · Phase 1
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02006290 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 19 participants.
The verdict
NCT02006290, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.
Interventions
- DRUG Placebo
- DRUG PF-06412562
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006290
The ClinicalTrials.gov registry entry for NCT02006290 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02006290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02006290 about?
NCT02006290 is a clinical study titled "Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease". The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.
What is the current status of trial NCT02006290?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-03. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02006290?
The interventions under investigation include: Placebo (DRUG), PF-06412562 (DRUG).
Who is sponsoring clinical trial NCT02006290?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.